3.740USD-5.56%Mkt Cap: 6.18M USDP/E: —Last update: 2026-06-01
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotama…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap6.18M USD
Enterprise Value10.64M USD
Revenue (TTM)2.00M USD
Gross Profit-41.07M USD
Net Income (TTM)-59.61M USD
Revenue/Share1.586 USD
Last Price3.740 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees41
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.94
PEG—
EV/EBITDA-0.21
EV/Revenue5.32
P/S3.26
P/B-0.17
EPS (TTM)-41.56
EPS (Forward)-1.34
52W Range
3.2601% of range71.50
52W High71.50 USD
52W Low3.260 USD
Profitability
Gross Margin0.00%
Oper. Margin-2519.95%
EBITDA Margin0.00%
Profit Margin-2980.35%
ROE164.71%
ROA-431.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-48.20M USD
CapEx (TTM)—
FCF Margin-901.62%
FCF Yield-291.77%
Net Debt4.13M USD
Net Debt/EBITDA-0.08
Balance Sheet
Debt/Equity-0.17
Current Ratio0.15
Quick Ratio0.10
Book Value/Sh-22.4810 USD
Cash/Share1.184 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateApr 6, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.66M
Float1.38M
Insiders5.63%
Institutions23.12%
Short Interest
Short Ratio4.7d
Short % Float9.83%
Short % Out.9.81%
Shares Short162.57K
Short (prev mo.)113.26K
Technical
SMA 505.266 (-29.0%)
SMA 20021.74 (-82.8%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)35.57K
Avg Vol (10d)36.42K
Technical Indicators
RSI (14)41.6
MACD-0.4039
MACD Signal-0.4734
MACD Hist.+0.0695
BB Upper4.910 USD
BB Middle4.183 USD
BB Lower3.456 USD
BB Width34.77%
ATR (14)0.5004 USD
Vol Ratio (20d)0.86x